IPO-bound pharmaceutical formulations company Sai Parenteral’s has acquired 74.6% stake in Adelaide-based Noumed Pharmaceuticals for ₹125 crore.
With AUD 60 million in revenue, Noumed is a supplier of private label over-the-counter (OTC) products to pharmacy chains across Australia and New Zealand. It is establishing a AUD 53 million manufacturing facility in Adelaide, which is expected to begin commercial operations by the fourth quarter of 2026.
With a portfolio of over 451 product dossiers, Noumed offers substantial breadth across therapeutic categories, Sai Parenteral said on Monday in a release on the acquisition.
This acquisition is in line with Sai Parenteral’s aspirations to become a global, innovation-led formulations and CDMO platform. “This partnership enhances our entry into semi-regulated and regulated markets with a wider, more competitive product portfolio, Managing Director Anil KK said.
Sai Parenterals had filed DRHP with SEBI, for initial public offering, in September 30. The IPO will comprise a fresh issue of up to ₹285 crore and an offer for sale of up to 35 lakh shares by existing shareholders.
“Having worked with Sai Parenteral’s for a considerable time, we are confident that together we can accelerate our product pipeline, benefit from Sai’s manufacturing capabilities and meet growing demand in the Australian, New Zealand and global markets,” Noumed managing director Mark Thulborne said.
Published – December 01, 2025 09:41 pm IST
